Abstract 2235
Background
Survivin is a protein that inhibits apoptosis and has been shown its role in cancer progression, tumor angiogenesis, tumor cell resistance to chemotherapeutics and ionizing radiation. We aimed to evaluate the importance of survivin in lung cancer patients and identify its role in disease progression and outcome.
Methods
We prospectively enrolled advanced non-small cell lung cancer (NSCLC) patients (2015-2017). Serum survivin expression levels were detected in the peripheral blood using real-time RT-PCR. The primary outcomes were to identify overall survival (OS), progression free survival (PFS) and time to progression (TTP) while the secondary outcomes were to identify the associations between different variables and survivin cut-off determined by receiver operating characteristic (ROC) curve. Chi(X2) and Mann Whitney-U tests were used. Kaplan-Meier survival curves were used and compared using Log-rank. Cox regression was used to identify if survivin was a predictor of survival.
Results
66 patients were recruited with median age of 55 years (Inter-quartile range: 47- 63.3), 74.2% were males. Adenocarcinoma represented 59.1%. 12 cases developed progressive disease (PD) with 8 cases had bone metastasis after PD. Median OS, TTP and PFS was 17.1 months (95%CI 13.1-20.9), 11.0 (95%CI 7.3-14.8) and 8.9 (95%CI 8.1-9.8) respectively. Chosen cut-off for survivin was 3.80 (Area under ROC curve=0.644 (95%CI=0.51-0.78), P = 0.044) that was associated with better median TTP and PFS of 12.0 vs 4.9 months and 9.0 vs 4.9 months in low survivin (≤ 3.8 vs high (>3.8) groups (P = 0.001 and 0.006) respectively. Survivin >3.80 was associated with worse TTP (Hazard ratio (HR) 5.66 (95%CI 1.8-17.7; P = 0.003). Higher survivin was associated with bone metastasis after PD (100% vs 26.3 in low survivin (P = 0.014).
Conclusions
Survivin is a significant predictors of time to progression and progression free survival in advanced NSCLC. Bone metastasis is common in high survivin group.Table: 164P
Kaplan Meier survival curves estimated median survival (in months) for survivin subgroups (≤3.80 vs > 3.80): A) overall survival (OS), B) time to progression (TP) and C) progression free survival (PFS) | ||||
---|---|---|---|---|
Median survival (months) | Lower CI | Upper CI | P-value | |
OS (overall) | 17.063 | 13.140 | 20.986 | |
- Survivin ≤3.80 | 17.063 | 0.156 | ||
- Survivin >3.80 | NR | |||
TTP (overall) | 11.047 | 7.327 | 14.766 | ------ |
- Survivin ≤3.80 | 12.000 | 0.001 | ||
- Survivin >3.80 | 4.964 | |||
PFS (overall) | 8.975 | 8.149 | 9.802 | ------ |
- Survivin ≤3.80 | 9.041 | 0.006 | ||
- Survivin >3.80 | 4.964 |
CI: 95% confidence interval, NR: not reached, OS: overall survival, PFS: progression free survival, TTP: time to progression
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract